BRIDGEBIO PHARMA Reports 97.8% Decrease in Revenue for Q2 2023

August 18, 2023

🌥️Earnings Overview

For the second quarter of fiscal year 2023, BRIDGEBIO PHARMA ($NASDAQ:BBIO) reported total revenue of USD 1.6 million, which was a 97.8% decrease from the same period in the prior year. Net income for the quarter was USD -157.9 million, a significant decrease from -9.9 million reported in the year prior.


GoodWhale has analyzed the fundamentals of BRIDGEBIO PHARMA and classified it as an “elephant”, a type of company that is rich in assets after deducting off liabilities. BRIDGEBIO PHARMA is strong in medium growth, however, it is weak in asset, dividend, and profitability. On a scale of 1 to 10, its health score is 2, indicating that it is less likely to sustain operations in times of crisis due to its cashflows and debt. Investors who are interested in BRIDGEBIO PHARMA would likely be those with a higher risk appetite since the company is in a weaker financial position. These investors may be looking for long-term investments where they can potentially benefit from capital appreciation due to the company being in a growth phase. They should also do their own research to evaluate whether the company is likely to succeed in the long run before investing. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Bridgebio Pharma. More…

    Total Revenues Net Income Net Margin
    5.67 -572.99 -10202.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Bridgebio Pharma. More…

    Operations Investing Financing
    -486.08 181.24 156.84
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Bridgebio Pharma. More…

    Total Assets Total Liabilities Book Value Per Share
    503.66 1.85k -8.49
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Bridgebio Pharma are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -48.1% -8875.2%
    FCF Margin ROE ROA
    -8600.5% 24.3% -62.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The competition among BridgeBio Pharma Inc and its competitors is fierce. All four companies are working to develop new and innovative treatments for various diseases and disorders. While each company has its own unique approach, they all share a common goal: to improve the lives of patients.

    – Faron Pharmaceuticals Oy ($LSE:FARN)

    Faron Pharmaceuticals Oy is a Finnish pharmaceutical company with a market cap of 148.02M as of 2022. The company’s Return on Equity is 1278.12%. Faron Pharmaceuticals Oy is engaged in the research and development of drugs for the treatment of cancer and other serious diseases. The company’s products include Traumakine, a drug for the treatment of traumatic brain injury, and Clevegen, a drug for the treatment of solid tumors.

    – Trevi Therapeutics Inc ($NASDAQ:TRVI)

    Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of nalbuphine ER to treat serious and debilitating conditions. Its product candidate, Nalbuphine ER, is an opioid analgesic that is in the late-stage clinical development for the treatment of pruritus in adult patients with Atopic Dermatitis, and for the treatment of chronic pruritus in adult patients with renal impairment.

    – IRLAB Therapeutics AB ($BER:6IRA)

    Diaverum is a Swedish renal care company. The company provides dialysis, peritoneal dialysis, and kidney transplantation services through a network of clinics in Europe, Asia-Pacific, the Middle East, and Latin America. Diaverum is a publicly traded company with a market capitalization of 161.21 million as of 2022. The company has a return on equity of -19.31%.


    BRIDGEBIO PHARMA‘s total revenue for the second quarter of fiscal year 2023 decreased dramatically by 97.8% compared to the prior year, resulting in a net income of USD -157.9 million. For investors, this is concerning as it suggests a lack of growth and profitability. It is important to further analyze BRIDGEBIO PHARMA’s financial performance to determine if the decreased revenue and income is a one-time issue or an ongoing trend. Investors should review current and historical financials, as well as any other relevant factors, to make an informed decision.

    Recent Posts

    Leave a Comment